Transfusion Medicine Reviews
Volume 21, Issue 1 , Pages 37-48 , January 2007

Anticoagulants and Their Reversal

  • Sam Schulman

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Sam Schulman, MD Thrombosis Service HHS-General Hospital 237 Barton Street East Hamilton, ON, Canada L8L 2X2.
    • ,
  • Nick R. Bijsterveld

References 

  1. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002;162:1833–1840
  2. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3:1843–1853
  3. Douketis JD, Arneklev K, Goldhaber SZ, et al. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: Assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding. Arch Intern Med. 2006;166:853–859
  4. Levine MN, Raskob G, Beyth RJ, et al. Hemorrhagic complications of anticoagulant treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:287S–310S
  5. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists. Chest. 2004;126:204S–233S(suppl)
  6. Fiore LD, Scola MA, Cantillon CE, et al. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis. 2001;11:175–183
  7. Crowther MA, Julian J, McCarty D. Treatment of warfarin-associated coagulopathy with oral vitamin K: A randomised controlled trial. Lancet. 2000;356:1551–1553
  8. Garcia DA, Regan S, Crowther M, et al. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006;47:804–808
  9. Yasaka M, Minematsu K, Naritomi H, et al. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost. 2003;89:278–283
  10. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11–28
  11. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): Third edition—2005 update. Br J Haematol. 2006;132:277–285
  12. Makris M, Greaves M, Phillips WS, et al. Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;77:477–480
  13. Lubetsky A, Hoffman R, Zimlichman R, et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res. 2004;113:371–378
  14. Schulman S. Care of patients receiving long-term anticoagulant therapy. N Engl J Med. 2003;349:675–683
  15. Deveras RA, Kessler CM. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med. 2002;137:884–888
  16. Freeman WD, Brott TG, Barrett KM, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc. 2004;79:1495–1500
  17. Lin J, Hanigan WC, Tarantino M, et al. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: Preliminary findings. J Neurosurg. 2003;98:737–740
  18. Sorensen B, Johansen P, Nielsen GL, et al. Reversal of the international normalized ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: Clinical and biochemical aspects. Blood Coagul Fibrinolysis. 2003;14:469–477
  19. Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res. 2006;Jul 12 [E-pub ahead of print]
  20. van Veen JJ, Laidlaw S, Maclean RM, et al. Clinical use of protamine for the emergency reversal of anticoagulation with low molecular weight heparin. J Thromb Haemost. 2005;3:Abstr 2049;(suppl 1)
  21. Lewis B, O'Leary M, Vinh T. Successful use of rVIIa (NovoSeven) to reverse enoxaparin (Lovenox) overdose in an adult patient with intracranial bleeding. Thromb Haemost. 2001;Abstr 2633;(suppl)
  22. Schick BP, Maslow D, Moshinski A, et al. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo. Blood. 2004;103:1356–1363
  23. Mixon TA, Dehmer GJ. Recombinant platelet factor 4 for heparin neutralization. Semin Thromb Hemost. 2004;30:369–377
  24. Stafford-Smith M, Lefrak EA, Qazi AG, et al. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology. 2005;103:229–240
  25. Malherbe S, Tsui BC, Stobart K, et al. Argatroban as anticoagulant in cardiopulmonary bypass in an infant and attempted reversal with recombinant activated factor VII. Anesthesiology. 2004;100:443–445
  26. Oh JJ, Akers WS, Lewis D, et al. Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin. Pharmacotherapy. 2006;26:569–577
  27. Wolzt M, Levi M, Sarich TC, et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost. 2004;91:1090–1096
  28. Elg M, Carlsson S, Gustafsson D. Effects of activated prothrombin complex concentrate or recombinant factor VIIa on bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res. 2001;101:145–157
  29. Diehl KH, Romisch J, Hein B, et al. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. Haemostasis. 1995;25:182–192
  30. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004;2:1700–1708
  31. Ibbotson SH, Grant PJ, Kerry R, et al. The influence of infusions of 1-desamino-8-d-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro. Thromb Haemost. 1991;65:64–66
  32. Bove CM, Casey B, Marder VJ. DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost. 1996;75:471–475
  33. Dickneite G, Nicolay U, Friesen HJ, et al. Development of an anti-bleeding agent for recombinant hirudin induced skin bleeding in the pig. Thromb Haemost. 1998;80:192–198
  34. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med. 2004;140:867–873
  35. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349:1695–1702
  36. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–1476
  37. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: The OASIS-6 randomized trial. JAMA. 2006;295:1519–1530
  38. PERSIST investigators . A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J Thromb Haemost. 2004;2:47–53
  39. Daud AN, Ahsan A, Iqbal O, et al. Synthetic heparin pentasaccharide depolymerization by heparinase I: Molecular and biological implications. Clin Appl Thromb Hemost. 2001;7:58–64
  40. Yu G, LeBrun L, Gunay NS, et al. Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. Thromb Res. 2000;100:549–556
  41. Gerotziafas GT, Depasse F, Chakroun T, et al. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost. 2004;91:531–537
  42. Bijsterveld NR, Moons AH, Meijers JC, et al. The impact on coagulation of an intravenous loading dose in addition to a subcutaneous regimen of low-molecular-weight heparin in the initial treatment of acute coronary syndromes. J Am Coll Cardiol. 2003;42:424–427
  43. Lisman T, Bijsterveld NR, Adelmeijer J, et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost. 2003;1:2368–2373
  44. Bijsterveld NR, Vink R, van Aken BE, et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br J Haematol. 2004;124:653–658
  45. Huvers F, Slappendel R, Benraad B, et al. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med. 2005;63:184–186
  46. Dao A, Tuan B, Carlson N. Reversal of a potent investigational anticoagulant: Idraparinux with recombinant factor VIIa. Am J Med. 2005;118:1172–1173
  47. Lee A, Agnelli G, Buller H, et al. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001;104:74–78
  48. Moons AH, Peters RJ, Bijsterveld NR, et al. Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty. J Am Coll Cardiol. 2003;41:2147–2153
  49. Friederich PW, Levi M, Bauer KA, et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation. 2001;103:2555–2559
  50. Rusconi CP, Yeh A, Lyerly HK, et al. Blocking the initiation of coagulation by RNA aptamers to factor VIIa. Thromb Haemost. 2000;84:841–848
  51. Becker RC, Rusconi CP, Sullenger BA. Nucleic acid aptamers in therapeutic anticoagulation. Thromb Haemost. 2005;93:1014–1020

PII: S0887-7963(06)00059-9

doi: 10.1016/j.tmrv.2006.08.002

Transfusion Medicine Reviews
Volume 21, Issue 1 , Pages 37-48 , January 2007

Article Tools